AlphaFold accelerates artificial intelligence powered drug discovery: efficient discovery of a novel CDK20 small molecule inhibitor. Issue 6 (17th January 2023)

• Record Type: Journal Article
• Authors: Ren, Feng; Ding, Xiao; Zheng, Min; Korzinkin, Mikhail; Cai, Xin; Zhu, Wei; Mantsyzov, Alexey; Aliper, Alex; Aladinskiy, Vladimir; Cao, Zhongying; Kong, Shanshan; Long, Xi; Man Liu, Bonnie Hei; Liu, Yingtao; Naumov, Vladimir; Shneyderman, Anastasia; Ozerov, Ivan V.; Wang, Ju; Pun, Frank W.; Polykovskiy, Daniil A.; Sun, Chong; Levitt, Michael; Aspuru-Guzik, Alán; Zhavoronkov, Alex
• Is Part Of: Chemical science. Volume 14:Issue 6(2023)
• Page Start: 1443
• Page End: 1452
• Publication Date: 2023-01-17
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/d2sc05709c
• Languages: English
• ISSNs: 2041-6520

Abstract

Abstract : A novel CDK20 small molecule inhibitor discovered by artificial intelligence based on an AlphaFold-predicted structure demonstrates the first application of AlphaFold in hit identification for efficient drug discovery. Abstract : The application of artificial intelligence (AI) has been considered a revolutionary change in drug discovery and development. In 2020, the AlphaFold computer program predicted protein structures for the whole human genome, which has been considered a remarkable breakthrough in both AI applications and structural biology. Despite the varying confidence levels, these predicted structures could still significantly contribute to structure-based drug design of novel targets, especially the ones with no or limited structural information. In this work, we successfully applied AlphaFold to our end-to-end AI-powered drug discovery engines, including a biocomputational platform PandaOmics and a generative chemistry platform Chemistry42. A novel hit molecule against a novel target without an experimental structure was identified, starting from target selection towards hit identification, in a cost- and time-efficient manner. PandaOmics provided the protein of interest for the treatment of hepatocellular carcinoma (HCC) and Chemistry42 generated the molecules based on the structure predicted by AlphaFold, and the selected molecules were synthesized and tested in biological assays. Through this approach, we identified a small molecule hit compound for cyclin-dependent kinase 20 (CDK20) with a binding constant Kd value of 9.2 ± 0.5 μM ( n = 3) within 30 days from target selection and after only synthesizing 7 compounds. Based on the available data, a second round of AI-powered compound generation was conducted and through this, a more potent hit molecule, ISM042-2-048, was discovered with an average Kd value of 566.7 ± 256.2 nM ( n = 3). Compound ISM042-2-048 also showed good CDK20 inhibitory activity with an IC50 value of 33.4 ± 22.6 nM ( n = 3). In addition, ISM042-2-048 demonstrated selective anti-proliferation activity in an HCC cell line with CDK20 overexpression, Huh7, with an IC50 of 208.7 ± 3.3 nM, compared to a counter screen cell line HEK293 (IC50 = 1706.7 ± 670.0 nM). This work is the first demonstration of applying AlphaFold to the hit identification process in drug discovery.